BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19776674)

  • 21. Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines.
    Poland PA; Kinlough CL; Rokaw MD; Magarian-Blander J; Finn OJ; Hughey RP
    Glycoconj J; 1997 Jan; 14(1):89-96. PubMed ID: 9076518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.
    Ciborowski P; Finn OJ
    Clin Exp Metastasis; 2002; 19(4):339-45. PubMed ID: 12090474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996.
    Price MR; Rye PD; Petrakou E; Murray A; Brady K; Imai S; Haga S; Kiyozuka Y; Schol D; Meulenbroek MF; Snijdewint FG; von Mensdorff-Pouilly S; Verstraeten RA; Kenemans P; Blockzjil A; Nilsson K; Nilsson O; Reddish M; Suresh MR; Koganty RR; Fortier S; Baronic L; Berg A; Longenecker MB; Hilgers J
    Tumour Biol; 1998; 19 Suppl 1():1-20. PubMed ID: 9422084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21.
    Adluri S; Gilewski T; Zhang S; Ramnath V; Ragupathi G; Livingston P
    Br J Cancer; 1999 Apr; 79(11-12):1806-12. PubMed ID: 10206297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
    Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
    Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential.
    Lohmueller JJ; Sato S; Popova L; Chu IM; Tucker MA; Barberena R; Innocenti GM; Cudic M; Ham JD; Cheung WC; Polakiewicz RD; Finn OJ
    Sci Rep; 2016 Aug; 6():31740. PubMed ID: 27545199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human colon adenocarcinomas express a MUC1-associated novel carbohydrate epitope on core mucin glycans defined by a monoclonal antibody (A10) raised against murine Ehrlich tumor cells.
    Medina M; Vélez D; Asenjo JA; Egea G; Real FX; Gil J; Subiza JL
    Cancer Res; 1999 Mar; 59(5):1061-70. PubMed ID: 10070964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mouse mucin 1 (MUC1) defined by monoclonal antibodies.
    Xing PX; Lees C; Lodding J; Prenzoska J; Poulos G; Sandrin M; Gendler S; McKenzie IF
    Int J Cancer; 1998 Jun; 76(6):875-83. PubMed ID: 9626356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat.
    Brokx RD; Revers L; Zhang Q; Yang S; Mal TK; Ikura M; Gariépy J
    Biochemistry; 2003 Dec; 42(47):13817-25. PubMed ID: 14636048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discrimination of MUC1 mucins from other sialyl-Le(a)-carrying glycoproteins produced by colon carcinoma cells using a novel monoclonal antibody.
    Baeckström D; Nilsson O; Price MR; Lindholm L; Hansson GC
    Cancer Res; 1993 Feb; 53(4):755-61. PubMed ID: 7679050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
    Barratt-Boyes SM; Vlad A; Finn OJ
    Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
    Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
    J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site.
    Wright SE; Kilinski L; Talib S; Lowe KE; Burnside JS; Wu JY; Dolby N; Dombrowski KE; Lebkowski JS; Philip R
    J Immunother; 2000 Jan; 23(1):2-10. PubMed ID: 10687132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epitope mapping of anti-MUC1 mucin protein core monoclonal antibodies.
    Petrakou E; Murray A; Price MR
    Tumour Biol; 1998; 19 Suppl 1():21-9. PubMed ID: 9422085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The production and characterization of novel heavy-chain antibodies against the tandem repeat region of MUC1 mucin.
    Rahbarizadeh F; Rasaee MJ; Forouzandeh M; Allameh A; Sarrami R; Nasiry H; Sadeghizadeh M
    Immunol Invest; 2005; 34(4):431-52. PubMed ID: 16302687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Products of Chemoenzymatic Synthesis Representing MUC1 Tandem Repeat Unit with T-, ST- or STn-antigen Revealed Distinct Specificities of Anti-MUC1 Antibodies.
    Yoshimura Y; Denda-Nagai K; Takahashi Y; Nagashima I; Shimizu H; Kishimoto T; Noji M; Shichino S; Chiba Y; Irimura T
    Sci Rep; 2019 Nov; 9(1):16641. PubMed ID: 31719620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
    Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
    Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and antibody recognition of synthetic antigens from MUC1.
    Bánóczi Z; Mezõ G; Windberg E; Uray K; Majer Z; Hudecz F
    J Pept Sci; 2008 May; 14(5):610-6. PubMed ID: 17975847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
    Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
    Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cystic fibrosis and pancreatic cancer cells synthesize and secrete MUC1 type mucin gene product.
    Dahiya R; Kwak KS; Ho SB; Yoon WH; Kim YS
    Biochem Mol Biol Int; 1995 Feb; 35(2):351-62. PubMed ID: 7545050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.